{"type":"trials","record":{"id":42010,"source_id":"clinicaltrials-gov","external_id":"NCT04304755","title":"Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)","brief_summary":"A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Oslo University Hospital","enrollment":40,"countries":["Norway"],"start_date":"2021-10-25","completion_date":"2024-01-24","last_update_date":"2024-04-05","source_url":"https://clinicaltrials.gov/study/NCT04304755","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"Z-AMD","age_range":"50 Years","comparator":"Placebo: NaCl 0,9%","organization":"Oslo University Hospital","interventions":["Zoledronic Acid 5 MG in 5 ML Injection","Placebos"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in best-corrected visual acuity (BCVA) after 52 weeks. — 52 weeks","The number of anti-VEGF intravitreal injections given after 52 weeks — 52 weeks","Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks. — 52 weeks","Proportion of patients with refractory nAMD after 52 weeks. — 52 weeks","EQ 5D score (ranging from 0-1; 0 designates \"perfect health\" and NEI-VFQ-25 score (ranging from 0 to 100 where 100 refl…","Mean change from baseline in Central retinal thickness (CRT) after 52 weeks. — 52 weeks","Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femo…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Zoledronic Acid 5 MG in 5 ML Injection","Placebos"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04304755","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-10-25 to 2024-01-24","comparator":"Placebo: NaCl 0,9%","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.907Z","intervention":["Zoledronic Acid 5 MG in 5 ML Injection","Placebos"],"participants":40,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in best-corrected visual acuity (BCVA) after 52 weeks. — 52 weeks","The number of anti-VEGF intravitreal injections given after 52 weeks — 52 weeks","Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks. — 52 weeks","Proportion of patients with refractory nAMD after 52 weeks. — 52 weeks","EQ 5D score (ranging from 0-1; 0 designates \"perfect health\" and NEI-VFQ-25 score (ranging from 0 to 100 where 100 refl…","Mean change from baseline in Central retinal thickness (CRT) after 52 weeks. — 52 weeks","Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femo…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42010","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}